| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2013110 | Pharmacology Biochemistry and Behavior | 2012 | 26 Pages |
Abstract
⺠Targeting glutamate holds great promise for improved treatment of anxiety disorders. ⺠Anxiolytic activity of mGluR2/3 agonists have achieved the greatest success to date. ⺠Positive and negative allosteric modulators offer an improved benefit/risk profile. ⺠Translational models of anxiety and stress disorders respond to glutamate modulation. ⺠Activity in standard anxiety tests must be replicated in translational animal models.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Brian H. Harvey, Mohammed Shahid,